Global Anti-angiogenic Ophthalmic Agent Supply, Demand and Key Producers, 2023-2029

Global Anti-angiogenic Ophthalmic Agent Supply, Demand and Key Producers, 2023-2029

The global Anti-angiogenic Ophthalmic Agent market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.

This report studies the global Anti-angiogenic Ophthalmic Agent production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Anti-angiogenic Ophthalmic Agent, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anti-angiogenic Ophthalmic Agent that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Anti-angiogenic Ophthalmic Agent total production and demand, 2018-2029, (K Units)

Global Anti-angiogenic Ophthalmic Agent total production value, 2018-2029, (USD Million)

Global Anti-angiogenic Ophthalmic Agent production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Anti-angiogenic Ophthalmic Agent consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: Anti-angiogenic Ophthalmic Agent domestic production, consumption, key domestic manufacturers and share

Global Anti-angiogenic Ophthalmic Agent production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global Anti-angiogenic Ophthalmic Agent production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Anti-angiogenic Ophthalmic Agent production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)

This reports profiles key players in the global Anti-angiogenic Ophthalmic Agent market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG and Santen Pharmaceutical Co., Ltd., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Anti-angiogenic Ophthalmic Agent market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Anti-angiogenic Ophthalmic Agent Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Anti-angiogenic Ophthalmic Agent Market, Segmentation by Type
Myopic Choroidal Neovascularization
Macular Edema
Diabetic Retinopathy
Macular Degeneration

Global Anti-angiogenic Ophthalmic Agent Market, Segmentation by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies

Companies Profiled:
Gilead Sciences, Inc.
Eyetech Inc.
Becton, Dickinson and Company
Regeneron Pharmaceuticals, Inc.
Genentech, Inc.
Novartis AG
Allergan plc
Bayer AG
Santen Pharmaceutical Co., Ltd.
Shanghai Pharmaceuticals
Johnson & Johnson
Pfizer
Sun Pharma
Otsuka Pharmaceutical Co. Ltd
Daiichi Sankyo
ERC Labs
Medicom Health care
Implant ophthalmic products GmbH
The Geuder Group, MORCHER GmbH
Novamedika

Key Questions Answered

1. How big is the global Anti-angiogenic Ophthalmic Agent market?

2. What is the demand of the global Anti-angiogenic Ophthalmic Agent market?

3. What is the year over year growth of the global Anti-angiogenic Ophthalmic Agent market?

4. What is the production and production value of the global Anti-angiogenic Ophthalmic Agent market?

5. Who are the key producers in the global Anti-angiogenic Ophthalmic Agent market?

6. What are the growth factors driving the market demand?